Detailed Information

Cited 3 time in webofscience Cited 3 time in scopus
Metadata Downloads

Treatment Response and Long-Term Outcome of Peginterferon alpha and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C

Authors
Jung, Chang HoUm, Soon HoKim, Tae HyungYim, Sun YoungSuh, Sang JunYim, Hyung JoonSeo, Yeon SeokChoi, Hyuk SoonChun, Hoon Jai
Issue Date
Sep-2016
Publisher
EDITORIAL OFFICE GUT & LIVER
Keywords
Hepatitis C virus clinical trials; Hepatitis C virus treatment; Hepatitis C, clinical; Viral hepatitis
Citation
GUT AND LIVER, v.10, no.5, pp.808 - 817
Indexed
SCIE
SCOPUS
KCI
Journal Title
GUT AND LIVER
Volume
10
Number
5
Start Page
808
End Page
817
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/6153
DOI
10.5009/gnl15360
ISSN
1976-2283
Abstract
Background/Aims: Peginterferon plus ribavirin remains a standard therapy for patients with chronic hepatitis C (CHC) in Korea. We investigated the efficacy and long-term outcome of peginterferon and ribavirin therapy in Korean patients with CHC, particularly in relation to the stage of liver fibrosis. Methods: The incidence of sustained virological response (SVR), hepatic decompensation, hepatocellular carcinoma, and liver-related death was analyzed in 304 patients with CHC; the patients were followed up for a median of 54 months. Results: Among patients with HCV genotype 1, the SVR rate was 36.7% (18/49) and 67% (69/103) for patients with and without cirrhosis, respectively (p<0.001). For patients with non-1 HCV genotypes, the SVR rates were 86.0% (37/43) in cirrhotic patients and 86.2% (94/109) in noncirrhotic patients. SVR significantly reduced the risk of liver related death, hepatic decompensation, and hepatocellular carcinoma, which had hazard ratios of 0.27, 0.16, and 0.22, respectively (all p<0.05). However, despite the SVR rate, patients with advanced fibrosis were still at risk of developing liver-related complications. Conclusions: A relatively high SVR rate was achieved by peginterferon plus ribavirin therapy in Korean patients with CHC, which improved their long-term outcomes. However, all CHC patients with advanced hepatic fibrosis should receive close follow-up observations, even after successful antiviral treatment.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Choi, Hyuk Soon photo

Choi, Hyuk Soon
Anam Hospital (Department of Gastroenterology and Hepatology, Anam Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE